Hormones
Where to Buy PT-141 in 2025: Telehealth, Clinic, and Research Prices
Compare PT-141 prices across telehealth, compounding clinics, and brand-name Vyleesi. Real costs from $99–$1,000+ per month with provider access details.
Where to Buy PT-141 in 2025: Telehealth, Clinic, and Brand-Name Prices Compared
Your libido used to just show up. Now it doesn't, and you're tired of being told to "reduce stress" or "try more foreplay." PT-141 (bremelanotide) is the one FDA-approved peptide that targets sexual desire at the brain level, and getting it ranges from $99/month to over $1,000/month depending on where you look and which version you choose.
Key Takeaways:
- Compounded PT-141 through telehealth runs $99–$300/month all-inclusive (consult, prescription, medication, shipping) as of mid-2025.
- In-person clinic visits add $150–$350 in initial consult fees on top of $50–$200/month for the medication itself.
- Brand-name Vyleesi retails at roughly $1,000+ per month (8 doses) without insurance, and most commercial plans don't cover it.
- The fastest route from sign-up to first injection is typically 5–10 business days through telehealth.
- Compounded PT-141 and brand-name Vyleesi contain the same active molecule (bremelanotide); the price gap is packaging, device, and markup.
---
Why PT-141 Pricing Is All Over the Map Right Now
You've probably already Googled this and gotten three wildly different numbers within five minutes. That's not a glitch. PT-141 exists in three distinct pricing tiers, and each one reflects a completely different supply chain.
Tier 1: Brand-name Vyleesi. AMAG Pharmaceuticals (now Covis Pharma) launched the FDA-approved autoinjector in June 2019 at a list price north of $900 for a pack of 8 single-use doses. Insurance coverage is spotty at best. The autoinjector is pre-filled at a fixed 1.75 mg dose, and the label restricts it to premenopausal women with acquired, generalized HSDD. If you're postmenopausal, your insurance won't touch it even if a provider writes the script.
Tier 2: Compounded PT-141 through telehealth. This is where most women are landing in 2025. Telehealth platforms contract with 503A compounding pharmacies (state-licensed, FDA-regulated facilities that prepare medications per individual prescription) to produce bremelanotide in multi-dose vials or pre-filled syringes. The provider consult, prescription, and medication ship together in a flat monthly fee. No separate pharmacy bill, no surprise lab charges.
Tier 3: Compounded PT-141 through in-person clinics. Functional medicine practices, hormone clinics, and sexual health specialists prescribe compounded bremelanotide with an office visit. You're paying for the consult and the medication separately, and the consult alone can run $150–$350 before you've filled anything.
The molecule is the same across all three tiers. The price difference is provider overhead, pharmacy type, device format, and whether you're subsidizing a brand name's marketing budget.
---
PT-141 Telehealth Prices: What $99–$300/Month Actually Gets You
Telehealth is the most popular access point for compounded PT-141 right now, and the pricing structures vary more than you'd expect.
PlexusDx runs a flat $189/month that bundles the provider consult, prescription, compounded PT-141 from a US 503A pharmacy, and shipping with no commitment tiers or per-dose surcharges. That's the all-inclusive model. Other peptide telehealth platforms structure it differently: some charge a lower base subscription ($99–$149/month) but bill separately for the medication or charge per vial.
What you're actually receiving at these price points:
- Provider consult (async or video, depending on the platform). Your prescriber will ask about your medical history, current medications, blood pressure baseline, and whether your low desire is situational or generalized. This isn't a rubber stamp. Uncontrolled hypertension is a real contraindication, and a responsible provider screens for it.
- Compounded bremelanotide in a multi-dose subcutaneous injection vial (typical) or pre-filled syringes (less common, sometimes at a premium). Dosing is provider-determined based on your history and response.
- Shipping from the 503A pharmacy, usually arriving in 5–10 business days after your consult is complete.
- Ongoing provider access for dose adjustments, side effect management, and refill authorization.
| Telehealth Feature | What to Expect |
|---|---|
| Monthly cost range | $99–$300/month (2025) |
| What's bundled | Consult, Rx, compounded medication, shipping |
| Pharmacy type | US 503A compounding pharmacy |
| Dosing format | Multi-dose vial (subcutaneous injection) or pre-filled syringes |
| Time to first dose | 5–10 business days from completed consult |
| State availability | Varies by platform; some exclude certain states due to telehealth prescribing laws |
| Commitment | Month-to-month on most platforms; some offer 3-month discounts |
One thing to check before you sign up: state availability. Telehealth prescribing regulations differ by state, and some platforms can't ship to every zip code. PlexusDx and similar services list their coverage maps upfront.
The optional add-on worth knowing about: PlexusDx offers a $99 genetics panel (one-time, post-enrollment) that covers 6 sexual health markers including eNOS variants, which can inform whether your provider adjusts your protocol. Not required, but it's the kind of personalization that separates a peptide-literate provider from a script mill.
---
PT-141 at Clinics: In-Person Pricing and What You're Paying For
If you have a complex medical history, uncontrolled blood pressure, or you just want someone to look you in the eye while explaining what you're injecting, an in-person clinic makes sense.
The cost structure is less predictable. You're typically looking at:
- Initial consultation: $150–$350, depending on the provider's specialty and your market. Functional medicine doctors and sexual health specialists tend to be at the higher end. Some hormone clinics fold the consult into a membership fee.
- Lab work: Not always required for PT-141 specifically, but many clinics run a baseline hormone panel (estradiol, testosterone, DHEA-S, thyroid) to rule out other contributors to low desire. Expect $100–$300 for labs if your insurance doesn't cover them.
- Medication: $50–$200/month for compounded bremelanotide, billed through the clinic's preferred compounding pharmacy. Some clinics mark up the medication; others pass through the pharmacy price at cost.
- Follow-up visits: $75–$200 per visit, typically every 2–3 months.
Add it all up and your first month at an in-person clinic can run $400–$850, settling to $150–$400/month ongoing.
When does this route make sense? When you have cardiovascular concerns that need monitoring (bremelanotide causes a small, transient blood pressure increase), when you're on multiple medications that need interaction review, or when you want your PT-141 prescribed as part of a broader hormone protocol that includes estrogen, testosterone, or progesterone. A provider managing your full hormonal picture can adjust everything together rather than treating desire in isolation.
The provider will want to know: your blood pressure (measured, not guessed), whether you're on any antihypertensives or nitrates, your current medications (especially SSRIs, which can cause the low desire you're trying to treat), and whether the desire loss is recent or longstanding. If it's longstanding and predates any relationship or medication change, they may want to explore other causes before prescribing.
---
Brand-Name Vyleesi: Who It's For and Why It Costs $1,000+
Vyleesi is the FDA-approved version of bremelanotide, delivered as a single-use autoinjector at a fixed 1.75 mg subcutaneous dose. The FDA approved it in June 2019 for premenopausal women with acquired, generalized HSDD.
The label language matters. "Acquired" means your desire was normal at some point and then declined. "Generalized" means it's not limited to one partner or one situation. If your low desire has been lifelong, or if it only applies to your current relationship, Vyleesi technically falls outside the approved indication. Providers can still prescribe off-label, but insurance won't cover an off-label use of a drug it barely covers on-label.
The money: Vyleesi's wholesale acquisition cost puts a box of 8 autoinjectors around $900–$1,000 (2025 pricing). At the label-maximum of 8 doses per month, that's your monthly ceiling. Most women don't use 8 doses monthly, so real-world monthly spend varies, but you're still paying per autoinjector, and the per-unit cost doesn't drop with lower usage.
Insurance reality: Most commercial plans either don't cover Vyleesi or require prior authorization with documentation of failed non-pharmacological treatment. Even with coverage, copays can run $50–$200 per fill. Covis Pharma has offered savings programs that can bring the out-of-pocket down to $0 for commercially insured patients, but these programs change terms frequently and don't apply to government insurance (Medicare, Medicaid, Tricare).
Who actually uses brand Vyleesi in 2025? Mostly women whose insurance does cover it after prior auth, or women who specifically want the FDA-approved product with the pre-filled autoinjector format (no drawing from a vial, no measuring). The autoinjector is genuinely easier to use if you're needle-averse. But at 5–10x the cost of compounded bremelanotide, most women who find their way to PT-141 choose the compounded route.
---
PT-141 Price Comparison: Telehealth vs. Clinic vs. Vyleesi
| Telehealth (Compounded) | In-Person Clinic (Compounded) | Brand-Name Vyleesi | |
|---|---|---|---|
| Monthly cost | $99–$300 | $150–$500 (medication + visits) | $900–$1,000+ (8 doses) |
| First-month cost | Same as monthly (consult bundled) | $400–$850 (consult + labs + medication) | $900–$1,000+ (or $0 with savings card) |
| What's included | Consult, Rx, medication, shipping | Consult and medication billed separately | Medication only; provider visit separate |
| Dosing format | Multi-dose vial or pre-filled syringes | Multi-dose vial (typically) | Single-use 1.75 mg autoinjector |
| Pharmacy type | 503A compounding | 503A compounding | Manufacturer (AMAG/Covis) |
| Provider access | Async or video; ongoing messaging | In-person visits every 2–3 months | Separate from medication purchase |
| Prescription required | Yes | Yes | Yes |
| Best for | Most women; fastest, simplest, cheapest | Complex medical history; multi-hormone protocols | Insurance-covered patients; needle-averse |
| Time to first dose | 5–10 business days | 1–3 weeks (scheduling + pharmacy) | Depends on pharmacy fill + prior auth |
The math is straightforward. If you're paying out of pocket and don't need in-person monitoring, telehealth compounded PT-141 is the most cost-effective option by a wide margin. If your insurance covers Vyleesi with a low copay, that's the easiest format. If you want PT-141 as part of a broader hormone protocol with hands-on oversight, a clinic is worth the premium.
---
How PT-141 Works and Why It's Different From Everything Else
PT-141 doesn't work like Viagra, Cialis, or any other sexual dysfunction drug you've heard of. Those are PDE5 inhibitors that increase blood flow to genital tissue. They address the plumbing. PT-141 addresses the wanting.
Bremelanotide is a melanocortin receptor agonist that activates MC4R and MC3R receptors in the hypothalamus and limbic system, the brain regions that govern sexual desire and arousal. It works on the central nervous system, not the vascular system. This is why women on PT-141 describe the effect as actually wanting sex again, not just being physically capable of having it.
The distinction matters because most women with low desire don't have a blood flow problem. They have a desire problem. The arousal pathways in the brain have downregulated, whether from hormonal shifts, medication side effects (SSRIs are notorious), stress, or perimenopause. PT-141 re-engages those pathways.
In the two Phase 3 clinical trials (Kingsberg et al., 2019, published in Obstetrics & Gynecology), bremelanotide significantly increased desire and reduced distress related to low desire compared to placebo over 24 weeks in over 1,200 premenopausal women. The effect was statistically significant on both co-primary endpoints: the Female Sexual Distress Scale (FSDS-DAO) and the Female Sexual Function Index desire domain (FSFI-D). Strong human evidence for the approved indication.
Women on compounded PT-141 protocols report the effect kicking in about 45 minutes after injection and lasting 6–12 hours, with the peak around 1–3 hours. What women describe most consistently: a return of spontaneous sexual thoughts and a physical sense of arousal that feels natural rather than forced. Not a switch-flip, but a noticeable shift in baseline desire.
Like most compounded peptides, PT-141 prescribed off the Vyleesi label (different doses, postmenopausal use, different frequencies) isn't covered by the FDA approval. That's worth knowing once, and then worth moving past, because the molecule and the mechanism are identical regardless of whether it comes in a branded autoinjector or a compounding pharmacy vial.
---
Side Effects and Safety: What the Clinical Data Actually Shows
Nausea is the headline side effect, and it's real. About 40% of women in the clinical trials experienced nausea after injection, most commonly with the first few doses. It typically improves with repeated use. Women on forums and in telehealth follow-ups report that anti-nausea strategies (taking it with a small meal, using ondansetron if prescribed, starting at a lower dose) make a real difference. Most women who stick past the first 2–3 doses find the nausea either resolves or becomes manageable.
Blood pressure: Bremelanotide causes a transient increase of approximately +6 mmHg systolic and +3 mmHg diastolic after dosing, resolving within 12 hours. For women with normal or well-controlled blood pressure, this is clinically insignificant. For women with uncontrolled hypertension, PT-141 is contraindicated. Your provider should check your BP before prescribing and may ask you to monitor at home.
Hyperpigmentation: About 1% of women in clinical trials developed darkening of the gums, face, or breasts. This is related to bremelanotide's activity at MC1R (the melanocortin receptor involved in pigmentation). It's generally reversible after discontinuation but can take months to fade. Worth knowing about, especially if you have darker skin tones where pigment changes are more visible.
Frequency limits: The FDA label caps use at 1 dose per 24 hours and no more than 8 doses per month. This ceiling exists because of the cardiovascular and nausea profile at higher frequencies. Your compounding provider may set a different cadence based on your response, but the 24-hour minimum between doses is a firm safety boundary.
Drug interactions to flag: PT-141 should not be used with naltrexone because bremelanotide may reduce naltrexone's effectiveness, a serious concern if you're using naltrexone to manage opioid or alcohol dependence. Alcohol can worsen nausea and the blood pressure effect. Women on SSRIs can typically use PT-141, and many do, since SSRIs are a common cause of the low desire they're treating. But your provider should review your full medication list.
The cardiovascular contraindication is the one hard line. If you have uncontrolled high blood pressure or significant cardiovascular disease, PT-141 is not appropriate until those are managed. This isn't a scare tactic. It's the reason a real provider consult matters and why a responsible telehealth platform asks about your BP before prescribing.
---
How to Get PT-141 Prescribed: Your Next Move
The process is simpler than you'd think, especially through telehealth.
Step 1: Take the provider quiz. Match with a telehealth platform or clinic that prescribes compounded PT-141 in your state. The quiz asks about your symptoms, medical history, and what you've already tried. It takes about 3 minutes.
Step 2: Complete your consult. Telehealth consults are typically asynchronous (a detailed intake form reviewed by a licensed provider) or a short video call. You'll be asked about your blood pressure, current medications, whether your low desire is acquired or lifelong, how long it's been going on, and whether you've tried other approaches. Be specific. The more detail you give, the better your provider can tailor the protocol.
Step 3: Get your prescription filled. If approved, your provider sends the prescription to a 503A compounding pharmacy. The pharmacy compounds your PT-141, and it ships directly to you. Most women receive their first shipment within 5–10 business days of completing the consult.
Step 4: Inject and assess. Your provider will give you timing and frequency guidance. Most protocols start conservative and adjust based on your response and side effect tolerance. Follow-up check-ins (typically via messaging on telehealth platforms) happen within the first 2–4 weeks.
The whole arc from "I'm interested" to "first injection" is usually under two weeks through telehealth. Through an in-person clinic, add another week or two for scheduling.
If you're not sure whether PT-141 is the right starting point or whether your low desire has hormonal roots that need addressing first, build your personal plan — it maps your symptoms to the most relevant protocols and providers.
[Take the provider quiz →]
---